- Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results